Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change.
We investigated the effect of carbamazepine (CBZ) cotreatment with haloperidol (HP) on cardiac change in Japanese psychiatric patients without heart disease. Of 21 patients cotreated with CBZ, 11 showed lengthening of QT interval corrected for heart rate (QTc) (> 440, mean percentage change, 29), of whom two patients developed congestive heart failure because of left ventricular dysfunction. Especially in these two patients, plasma HP levels were significantly higher than speculated from the correlations. It is possible to speculate that, especially on CBZ cotreatment, significantly higher HP plasma level with QTc prolongation may herald heart failure.
Iwahashi
K
K
Department of Neuropsychiatry, Kagawa Medical School, Japan.
D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D002220:Carbamazepine; D006220:Haloperidol